论文部分内容阅读
目的观察微生态制剂辅助治疗新生儿高胆红素血症的临床疗效。方法将60例高胆红素血症新生儿随机分为对照组和治疗组各30例,对照组行常规治疗,治疗组在常规治疗基础上加服双歧三联活菌制剂。分别于治疗前和治疗后1、4、7 d检测患儿血清总胆红素水平,观察两组患儿黄疸消退时间及评价疗效。结果治疗组和对照组治疗后第4天和第7天血清总胆红素比较,差异有统计学意义(P<0.05);两组患儿黄疸消退时间比较差异有统计学意义(P<0.05)。结论采用双歧三联活菌制剂辅助治疗新生儿高胆红素血症,可明显缩短患儿黄疸消退时间和治疗时间,可作为治疗新生儿高胆红素血症的辅助药物。
Objective To observe the clinical efficacy of probiotics in the treatment of neonatal hyperbilirubinemia. Methods Sixty newborn infants with hyperbilirubinemia were randomly divided into control group and treatment group, 30 cases in each group. The control group was treated routinely. The treatment group received Bifidobacterium triple viable agent on the basis of routine treatment. The level of serum total bilirubin in children was measured before treatment and at 1, 4 and 7 days after treatment. The jaundice subsided time and the curative effect were observed in both groups. Results The serum total bilirubin in the treatment group and the control group on the 4th and 7th day after treatment was significantly different (P <0.05). There was significant difference between the two groups in the regression time of jaundice (P <0.05 ). Conclusion Using bifidobacterium triple viable preparations as adjuvant treatment of neonatal hyperbilirubinemia can significantly reduce jaundice in children with subsided time and treatment time, can be used as an adjunct to the treatment of neonatal hyperbilirubinemia.